©2018 WebMD, Inc. All rights reserved. eMedicineHealth does not provide medical advice, diagnosis or treatment. See Additional Information.

Scopolia

What other names is Scopolia known by?

Belladonna, Belladonna Scopola, Escopolia, Glockenbilsenkraut, Japanese Belladonna, Russian Krainer Tollkraut, Scopola, Scopolia carniolica, Scopoliae Rhizoma, Scopolie.

What is Scopolia?

Scopolia is a plant. The root and root-like stem (rhizome) are used as medicine.

Despite serious safety concerns, scopolia is used for spasms of the digestive tract, bile ducts, and urinary tract; and for liver and gallbladder complaints. Scopolia is also used to increase urine production, cause relaxation and sleep, dilate eye pupils, and relieve pain.

Insufficient Evidence to Rate Effectiveness for...

  • Fluid retention.
  • Anxiety.
  • Trouble sleeping.
  • Pain.
  • Liver problems.
  • Gallbladder problems.
  • Spasms of the digestive tract.
  • Other conditions.
More evidence is needed to rate the effectiveness of scopolia for these uses.

How does Scopolia work?

Scopolia contains several chemicals which are similar to prescription medications, including hyoscyamine, atropine, and scopolamine. These chemicals relax muscles lining the digestive and urinary tracts.

Are there safety concerns?

Scopolia is LIKELY UNSAFE when taken by mouth for self-medication. There is only a small difference between a beneficial dose and a poisonous dose, and products vary in concentrations of chemicals. Early symptoms of poisoning include reddened skin and dry mouth. Other symptoms include high body temperature, vision problems, difficulty urinating, and constipation. Taking large amounts of scopolia can cause restlessness, compulsive speech, and hallucinations, followed by breathing problems, and death.

Special Precautions & Warnings:

It is LIKELY UNSAFE for anyone to use scopolia, but people with the following conditions are especially likely to experience unwanted side effects:

Pregnancy and breast-feeding: Scopolia is LIKELY UNSAFE. Don't use it if you are pregnant or breast-feeding.

Heart problems such as congestive heart failure (CHF) or rapid, irregular heartbeat: Scopolia might make heart problems worse. Don't use it if you have one of these conditions.

Down syndrome: People with Down syndrome might be especially sensitive to the harmful effects of scopolia. Don't give it to them.

Hiatal hernia or heartburn (esophageal reflux disease): Scopolia might make esophageal reflux disease worse. Don't use it if you have this condition.

Fever: Scopolia might raise the body temperature. Don't use it if you have a fever.

Digestive tract conditions including constipation, stomach ulcers, stomach or intestinal infections, ulcerative colitis, enlarged colon (toxic megacolon), or blockage of the digestive tract: Scopolia might make digestive tract problems worse. Don't use it if you have one of these conditions.

Narrow-angle glaucoma: Scopolia might make narrow-angle glaucoma worse. Don't use it if you have this condition.

Trouble urinating (urinary retention): Scopolia might make urinary retention worse. Don't use it if you have this condition.

QUESTION

Next to red peppers, you can get the most vitamin C from ________________. See Answer

Are there any interactions with medications?


Drying medications (Anticholinergic drugs)Interaction Rating: Major Do not take this combination.

Scopolia contains chemicals that cause a drying effect. It also affects the brain and heart. Drying medications called anticholinergic drugs can also cause these effects. Taking scopolia and drying medications together might cause side effects including dry skin, dizziness, low blood pressure, fast heartbeat, and other serious side effects.

Some of these drying medications include atropine, scopolamine, and some medications used for allergies (antihistamines), and for depression (antidepressants).


Medications used for depression (Tricyclic antidepressants)Interaction Rating: Major Do not take this combination.

Scopolia contains chemicals that can affect the body. Some of these chemicals have effects similar to some medications used for depression. Taking scopolia might increase the side effects of some medications used for depression.

Some of these medicines used for depression include amitriptyline (Elavil), imipramine (Tofranil), and others.


QuinidineInteraction Rating: Major Do not take this combination.

Scopolia can affect the heart. Quinidine can also affect the heart. Taking quinidine along with scopolia might cause serious heart problems.

Dosing considerations for Scopolia.

The appropriate dose of scopolia depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for scopolia. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

Health Solutions From Our Sponsors

Reviewed on 9/17/2019
References

Abernethy, A. P., Nixon, A., Fine, P. G., Peppin, J. F., Crossno, R. J., and Bull, J. Palliative care pharmacotherapy literature summaries and analyses. J Pain Palliat.Care Pharmacother. 2007;21(3):91-97. View abstract.

Adigun, A. O. and Ajayi, A. A. Muscarinic blockade with oral hyoscine palliates angiotensin converting enzyme inhibitor induced cough. Afr.J Med Med Sci 1998;27(1-2):139. View abstract.

Ahveninen, J., Tiitinen, H., Hirvonen, J., Pekkonen, E., Huttunen, J., Kaakkola, S., and Jaaskelainen, I. P. Scopolamine augments transient auditory 40-hz magnetic response in humans. Neurosci.Lett. 12-24-1999;277(2):115-118. View abstract.

Al-Waili, N. and Saloom, K. Y. The analgesic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide. Eur J Med Res 10-14-1998;3(10):475-479. View abstract.

Alberch J, Carman-Krzan M, Fabrazzo M, and et al. Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. Brain Res 3-1-1991;542(2):233-240. View abstract.

Alhalel, A., Ziv, I., Versano, D., Ruach, M., Alkalay, M., Almog, S., Izraeli, S., and Glovinsky, J. Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. Aviat.Space Environ Med 1995;66(11):1037-1040. View abstract.

Ali-Melkkilä T, Kanto J, and Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993;37:633-642.

Alihanka J, Lahdenpera A, and Kaila T. The effects of transdermal scopolamine on autonomic nervous activity during sleep. Eur.J Clin Pharmacol 1994;46(6):507-510. View abstract.

Anderson, D. R., Harris, L. W., Bowersox, S. L., Lennox, W. J., and Anders, J. C. Efficacy of injectable anticholinergic drugs against soman-induced convulsive/subconvulsive activity. Drug Chem Toxicol 1994;17(2):139-148. View abstract.

Anonymous. Transdermal scopolamine for motion sickness. Medical Letter on Drugs and Therapeutics 10-16-1981;23(21):89-90. View abstract.

Antrobus, J. H., Abbott, P., Carr, C. M., and Chatrath, R. R. Midazolam-droperidol premedication for cardiac surgery. A comparison with papaveretum and hyoscine. Anaesthesia 1991;46(5):407-409. View abstract.

Aronson, J. K. and Sear, J. W. Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia 1986;41(1):1-3. View abstract.

Attias J, Gordon C, Ribak J, and et al. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat.Space Environ.Med 1987;58(1):60-62. View abstract.

Babin R, Balkany T, and Fee W. Transdermal scopolamine in the treatment of acute vertigo. Ann.Otol.Rhinol.Laryngol. 1984;93(1 Pt 1):25-27. View abstract.

Bahro M, Schreurs B, Sunderland T, and et al. The effects of scopolamine, lorazepam, and glycopyrrolate on classical conditioning of the human eyeblink response. Psychopharmacology (Berl) 1995;122(4):395-400. View abstract.

Bailey, P. L., Streisand, J. B., Pace, N. L., Bubbers, S. J., East, K. A., Mulder, S., and Stanley, T. H. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 1990;72(6):977-980. View abstract.

Bajalan A, Wright C, and van, der Vliet V. Changes in the human visual evoked potential caused by the anticholinergic agent hyoscine hydrobromide: comparison with results in Alzheimer's disease. J.Neurol.Neurosurg.Psychiatry 1986;49(2):175-182. View abstract.

Beach GO, Fitzgerald RP, Holmes R, and et al. Hazards to health: scopolamine poisoning*. New England Journal of Medicine 1964;270(25):1354-1355.

Beatty W, Butters N, and Janowsky D. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav.Neural Biol. 1986;45(2):196-211. View abstract.

Beatty, W. W. and Bierley, R. A. Scopolamine degrades spatial working memory but spares spatial reference memory: dissimilarity of anticholinergic effect and restriction of distal visual cues. Pharmacol Biochem.Behav. 1985;23(1):1-6. View abstract.

Becker, G., Goossens, H., Seemann, K., Souchon, F., and Weitz, T. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy]. Dtsch Med Wochenschr 12-7-1984;109(49):1881-1885. View abstract.

Bennett, M. I. Death rattle: an audit of hyoscine (scopolamine) use and review of management. J Pain Symptom.Manage. 1996;12(4):229-233. View abstract.

Benson, A. J. and Brand, J. J. Some effects of l-hyoscine hydrobromide on post-rotatory sensation and nystagmus in man. Q J Exp Physiol Cogn Med Sci 1968;53(3):296-311. View abstract.

Bernstein S and Leff R. Toxic psychosis from sleeping medicines containing scopolamine. N.Engl.J Med 9-21-1967;277(12):638-639. View abstract.

Bettermann, H., Cysarz, D., Portsteffen, A., and Kummell, H. C. Bimodal dose-dependent effect on autonomic, cardiac control after oral administration of Atropa belladonna. Auton.Neurosci. 7-20-2001;90(1-2):132-137. View abstract.

Bienia, R. A., Smith, M., and Pellegrino, T. Scopolamine skin-disks and anisocoria. Ann Intern Med 1983;99(4):572-573. View abstract.

Biggan S, Ingles J, and Beninger R. Scopolamine differentially affects memory of 8- and 16-month-old rats in the double Y-maze. Neurobiol.Aging 1996;17(1):25-30. View abstract.

Binah O, Gordon C, Attias J, and et al. Transdermal scopolamine (Scopoderm

Bishop KI, Curran HV, and Lader M. Do scopolamine and lorazepam have dissociable effects on human memory systems? A dose--response study with normal volunteers. Exp Clin Psychopharmacol 1996;4(3):292-299.

Bishop, K. I. and Curran, H. V. An investigation of the effects of benzodiazepine receptor ligands and of scopolamine on conceptual priming. Psychopharmacology (Berl) 1998;140(3):345-353. View abstract.

Bliem, B., Tegenthoff, M., and Dinse, H. R. Cholinergic gating of improvement of tactile acuity induced by peripheral tactile stimulation. Neurosci.Lett. 3-21-2008;434(1):129-132. View abstract.

Blin J and Chase T. Effects of scopolamine on human brain glucose consumption. Neuropsychopharmacology 1995;12(3):273-276. View abstract.

Blin J, Piercey M, Giuffra M, and et al. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. J Neurol Sci. 1994;123(1-2):44-51. View abstract.

Bosek V and Downs JB. Nausea and vomiting after Alfentanil anesthesia: effect of transdermal scopolamine. Anesthesiol Rev 1992;19(1):19-22.

Bosman IJ. Chapter 8. Effects of transdermal scopolamine on pulmonary function and symptoms in patients with (partially) reversible airways obstruction. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.

Bosman IJ. Chapter 9. Effects of transdermal scopolamine on bronchial hyperresponsiveness to methacholine. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.

Bova, J. G., Jurdi, R. A., and Bennett, W. F. Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral hyoscyamine, i.v. glucagon, and no drug. AJR Am J Roentgenol. 1993;161(5):965-968. View abstract.

Braccini G., Marraccini P, Marrucci A, and et al. Usefulness and safety of pirenzepine in double-contrast study of upper gastrointestinal tract: comparison with scopolamine methylbromide. Abdom.Imaging 1994;19(3):201-206. View abstract.

Braccini, G., Marraccini, P., Boraschi, P., Marrucci, A., Bertellotti, L., and Testa, R. [Usefulness of pirenzepine in the study of the upper digestive tract and the large intestine with double contrast media: comparison with scopolamine methylbromide]. Radiol.Med (Torino) 1996;92(6):733-737. View abstract.

Bradford, T. H., Robertson, K., Norman, P. F., and Meeks, G. R. Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. Obstet Gynecol 1995;85(5 Pt 1):687-691. View abstract.

Brand, J. J. and Whittingham, P. Intramuscular hyoscine in control of motion sickness. Lancet 8-1-1970;2(7666):232-234. View abstract.

Brand, J. J., Colquhoun, W. P., and Perry, W. L. Side-effects of 1-hyoscine and cyclizine studied by objective tests. Aerosp.Med 1968;39(9):999-1002. View abstract.

Brand, J. J., Colquhoun, W. P., Gould, A. H., and Perry, W. L. (--)-Hyoscine and cyclizine as motion sickness remedies. Br.J Pharmacol. 1967;30(3):463-469. View abstract.

Brandeis D, Naylor H, Halliday R, and et al. Scopolamine effects on visual information processing, attention, and event-related potential map latencies. Psychophysiology 1992;29(3):315-336. View abstract.

Brazell C, Preston GC, Ward C, and et al. The scopolamine model of dementia: chronic transdermal administration. J Psychopharmacol 1989;3(2):76-82.

Brodtkorb E, Wyzocka-Bakowska M, Lillevold P, and . Transdermal scopolamine in drooling. J Ment.Defic.Res 1988;32 ( Pt 3):233-237. View abstract.

Broks P, Preston G, Traub M, and et al. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 1988;26(5):685-700. View abstract.

Brooks, A. M., West, R. H., and Gillies, W. E. The risks of precipitating acute angle-closure glaucoma with the clinical use of mydriatic agents. Med J Aust 7-7-1986;145(1):34-36. View abstract.

Brown K and Warburton DM. Attenuation of stimulus sensitivity by scopolamine. Psychon Sci 1971;22(5):297-298.

Buchhalter, A. R., Fant, R. V., and Henningfield, J. E. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008;68(8):1067-1088. View abstract.

Caine E, Weingartner H, Ludlow C, and et al. Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology (Berl) 1981;74(1):74-80. View abstract.

Cairncross J. Scopolamine psychosis revisited. Ann.Neurol. 1983;13(5):582. View abstract.

Callaway, E., Halliday, R., Naylor, H., and Schechter, G. Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology (Berl) 1985;85(2):133-138. View abstract.

Capacio B and Shih T. Anticonvulsant actions of anticholinergic drugs in soman poisoning. Epilepsia 1991;32(5):604-615. View abstract.

Carlston J. Unilateral dilated pupil from scopolamine disk. JAMA 7-2-1982;248(1):31. View abstract.

Casadei B, Conway J, Forfar C, and et al. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 1996;75(3):274-280. View abstract.

Casadei B, Conway J, Meyer TE, and et al. Effect of vagal stimulation by transdermal scopolamine on exercise performance and R-R interval variability (RRV) in patients with chronic heart failure (CHF) [abstract]. Circulation 1992;86 (Suppl 1):I-395.

Casadei B, Pipilis A, Conway J, and et al. Effects of vagal stimulation by transdermal scopolamine in patients post myocardial infarction [abstract]. Circulation 1991;84 (Suppl 2):II-555.

Casadei B, Pipilis A, Sessa F, and et al. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation 1993;88(2):353-357. View abstract.

Casadei B, Pipilis A, Sessa F, and et al. Transdermal scopolamine: a potential tool in preventing sudden death in myocardial infarction [abstract]. Eur Heart J 1991;12 (Suppl):366.

Chan, T. Y. An assessment of the delayed effects associated with valerian overdose. Int.J Clin Pharmacol.Ther. 1998;36(10):569. View abstract.

Chan, T. Y., Tang, C. H., and Critchley, J. A. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian). Postgrad.Med.J 1995;71(834):227-228. View abstract.

Chandrasekaran SK. Controlled release of scopolamine for prophylaxis of motion sickness. Drug Development and Industrial Pharmacy 1983;9(4):627-646.

Chiaramonte, J. S. Cycloplegia from transdermal scopolamine. N Engl J Med 1-21-1982;306(3):174. View abstract.

Christensen, C. M., Navazesh, M., and Brightman, V. J. Effects of pharmacologic reductions in salivary flow on taste thresholds in man. Arch Oral Biol 1984;29(1):17-23. View abstract.

Chung-Hua H. [Successful use of scopolamine in acute myocardial infarction associated with resistant ventricular tachycardia]. Chin J Cardiol 1986;14(5):282-283.

Ciccaglione, A. F., Grossi, L., Cappello, G., Malatesta, M. G., Ferri, A., Toracchio, S., and Marzio, L. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96(8):2306-2311. View abstract.

Clarke RS, Dundee JW, and Moore J. Studies of drugs given before anaesthesia. VI. Atropine and hyoscine. Br J Anaesth 1964;36:648-654.

Clarke, R. S., Dundee, J. W., and Love, W. J. Studies of drugs given before anaesthesia. 8. Morphine 10 mg alone and with atropine or hyoscine. Br J Anaesth 1965;37(10):772-778. View abstract.

Clarke, R. S., Dundee, J. W., and MOORE, J. STUDIES OF DRUGS GIVEN BEFORE ANAESTHESIA. IV. ATROPINE AND HYOSCINE. Br.J Anaesth. 1964;36:648-654. View abstract.

Clissold S and Heel R. Transdermal hyoscine (scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29(3):189-207. View abstract.

Cohen R, Gross M, Semple W, and et al. The metabolic brain pattern of young subjects given scopolamine. Exp Brain Res 1994;100(1):133-143. View abstract.

Colquhoun WP. Effects of hyoscine and meclozine on vigilance and short-term memory. Br J Industr Med 1962;19:287-296.

Conner, J. T., Bellville, J. W., Wender, R., Schehl, D., Dorey, F., and Katz, R. L. Morphine, scopolamine, and atropine as intravenous surgical premedicants. Anesth.Analg. 1977;56(5):606-614. View abstract.

Cornella J, Bent A, Ostergard D, and et al. Prospective study utilizing transdermal scopolamine in detrusor instability. Urology 1990;35(1):96-97. View abstract.

Cronin, C. M., Sallan, S. E., and Wolfe, L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982;2(1):29-31. View abstract.

Crowell, E. B., Jr. and Ketchum, J. S. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther 1967;8(3):409-414. View abstract.

Curran H, Pooviboonsuk P, Dalton J, and et al. Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine. Psychopharmacology (Berl) 1998;135(1):27-36. View abstract.

Curran H, Schifano F, and Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology (Berl) 1991;103(1):83-90. View abstract.

Dahl E, Offer-Ohlsen D, Lillevold P, and et al. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984;36(1):116-120. View abstract.

Danion J, Zimmermann M, Willard-Schroeder D, and et al. Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers. Psychopharmacology (Berl) 1990;102(3):422-424. View abstract.

De Ferrari G, Mantica M, Vanoli E, et al, and . Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. J Am.Coll.Cardiol. 11-1-1993;22(5):1327-1334. View abstract.

De Ferrari GM, Mantica M, Curcuruto P, and et al. Transdermal scopolamine modifies autonomic balance after myocardial infarction [abstract]. Circulation 1991;84(4):II-266.

Degioanni JJ, Calkins DS, and Reschke MF. Evaluation of the efficacy of buccal scopolamine tablets (1.0 mg) in the treatment of acute motion sickness [abstract]. Aviat Space Environ Med 1990;61:484.

Demeter, S. L. and Cordasco, E. M. Transdermal scopolamine in the treatment of asthma: a preliminary report. J Asthma 1986;23(4):203-206. View abstract.

Dettman C. Suppression of salivation in wind-instrument players with scopolamine. N.Engl.J.Med. 5-24-1984;310(21):1396. View abstract.

Dibner-Dunlap M, Eckberg D, Magid N, and et al. The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine. Circulation 1985;71(4):797-804. View abstract.

Dibner-Dunlap ME, Eckberg DL, and Magid NM. Transcutaneous scopolamine: a potential defense against sudden cardiac death [abstract]. Clin Res 1984;32(2):473A.

Done AK. The toxic emergency. To sleep, perchance to die. Emergency Medicine 1975;7:277-279, 283, 287-289.

Dotevall, G., Walan, A., and Weinfeld, A. Effect of 1-hyoscyamine on gastric secretion of acid and intrinsic factor in man. Gut 1967;8(3):276-280. View abstract.

Douma WR, Bosman IJ, Rutgers SR, and et al. Effects of transdermal scopolamine on pulmonary function, symptoms and bronchial hyperresponsiveness to methacholine. Eur J Pharm Sci 1998;5(6):327-334.

Doyle, E., Byers, G., McNicol, L. R., and Morton, N. S. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br J Anaesth. 1994;72(1):72-76. View abstract.

Dreyfuss P, Vogel D, and Walsh N. The use of transdermal scopolamine to control drooling. A case report. Am J Phys.Med Rehabil. 1991;70(4):220-222. View abstract.

Duka T, Redemann B, and Voet B. Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. Psychopharmacology (Berl) 1995;119(3):315-324. View abstract.

Dukoff R, Friz J, Lasser, and et al. A comparison of effects of tacrine with scopolamine versus tacrine with placebo in patients with Alzheimer's disease [abstract]. 11th Annual Meeting of the American Association for Geriatric Psychiatry 1998;

Dumas, J., Hancur-Bucci, C., Naylor, M., Sites, C., and Newhouse, P. Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis. Horm.Behav. 2008;53(1):159-169. View abstract.

Dundee, J. W. and Pandit, S. K. Anterograde amnesic effects of pethidine, hyoscine and diazepam in adults. Br.J Pharmacol 1972;44(1):140-144. View abstract.

Dunne M and Hartley L. The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. Acta Psychol.(Amst) 1985;58(3):205-217. View abstract.

Dunne MP. Scopolamine and sustained retrieval from semantic memory. J Psychopharmacol 1990;4(1):13-18.

Dunne, M. P. and Hartley, L. R. Scopolamine and the control of attention in humans. Psychopharmacology (Berl) 1986;89(1):94-97. View abstract.

Eberhart, L. H., Holzrichter, P., and Roscher, R. [Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients]. Anaesthesist 1996;45(3):259-267. View abstract.

Ebert U, Oertel R, Wesnes KA, and et al. Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. Hum Psychopharmacol 1998;13:199-210.

Ebert, U., Siepmann, M., Oertel, R., Wesnes, K. A., and Kirch, W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998;38(8):720-726. View abstract.

Einarsson, J. I., Audbergsson, B. O., and Thorsteinsson, A. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial. J Minim.Invasive.Gynecol. 2008;15(1):26-31. View abstract.

Elias M and Abouleish E. Scopolamine patch can be confusing to the patient and anesthesiologist: a case report. Anesthesiology 1997;86(3):743-744. View abstract.

Estrada, A., Leduc, P. A., Curry, I. P., Phelps, S. E., and Fuller, D. R. Airsickness prevention in helicopter passengers. Aviat.Space Environ.Med 2007;78(4):408-413. View abstract.

Evens, R. P. and Leopold, J. C. Scopolamine toxicity in a newborn. Pediatrics 1980;66(2):329-330. View abstract.

Feinberg, M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3(4):335-348. View abstract.

Ferris, F. D., Kerr, I. G., Sone, M., and Marcuzzi, M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom.Manage 1991;6(6):389-393. View abstract.

Firth, A. Y. and Walker, K. Visual side-effects from transdermal scopolamine (hyoscine). Dev.Med Child Neurol. 2006;48(2):137-138. View abstract.

Flicker C, Ferris S, and Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) 1992;107(2-3):437-441. View abstract.

Flicker C, Serby M, and Ferris S. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl) 1990;100(2):243-250. View abstract.

Fraunfelder, F. T. Transdermal scopolamine precipitating narrow-angle glaucoma. N Engl J Med 10-21-1982;307(17):1079. View abstract.

Fredrickson, A., Snyder, P. J., Cromer, J., Thomas, E., Lewis, M., and Maruff, P. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum.Psychopharmacol. 2008;23(5):425-436. View abstract.

Frith, C. D., Richardson, J. T., Samuel, M., Crow, T. J., and McKenna, P. J. The effects of intravenous diazepam and hyoscine upon human memory. Q J Exp Psychol A 1984;36(1):133-144. View abstract.

Frumin, M. J., Herekar, V. R., and Jarvik, M. E. Amnesic actions of diazepam and scopolamine in man. Anesthesiology 1976;45(4):406-412. View abstract.

Fujii, Y. Clinical strategies for preventing postoperative nausea and vomitting after middle ear surgery in adult patients. Curr.Drug Saf 2008;3(3):230-239. View abstract.

Furey, M. L. and Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch.Gen.Psychiatry 2006;63(10):1121-1129. View abstract.

Furey, M. L., Pietrini, P., Haxby, J. V., and Drevets, W. C. Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology 2008;33(4):913-923. View abstract.

Galeone M, Cacioli, D, Megevand J, and et al. Selection of the first-line treatment of irritable bowel syndrome - a prospective, randomised evaluation of fenoverine and hyoscine butyl bromide. European Journal of Clinical Research 1992;3:157-170.

Garner HH and Martinez S. Toxic psychosis due to a hyoscine compound. Illinois Medical Journal 1958;114:122-123.

Gibbons PA, Nicolson SC, Betts EK, and et al. Scopolamine does not prevent post-operative emesis after pediatric eye surgery. Anesthesiology 1984;61(3A):A435.

Gillin J, Sutton, L., Ruiz C, and et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol.Psychiatry 7-15-1991;30(2):157-169. View abstract.

Giovannini, M. G. The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev.Neurosci. 2006;17(6):619-634. View abstract.

Gleiter, C. H., Antonin, K. H., and Bieck, P. R. Transdermally applied scopolamine does not impair psychomotor performance. Psychopharmacology (Berl) 1984;83(4):397-398. View abstract.

Gleiter, C. H., Antonin, K. H., Brodrick, T., Bieck, P. R., and Breucha, G. Transdermal scopolamine and basal acid secretion. N Engl J Med 11-22-1984;311(21):1378. View abstract.

Golding J, Gosden E, and Gerrell J. Scopolamine blood levels following buccal versus ingested tablets. Aviat.Space Environ.Med 1991;62(6):521-526. View abstract.

Golding, J. F. and Stott, J. R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br.J Clin.Pharmacol. 1997;43(6):633-637. View abstract.

Goldstein, B. J. Scopolamine-induced acute brain syndrome. J Fla.Med.Assoc. 1966;53(5):413-414. View abstract.

Good W and Crain L. Esotropia in a child treated with a scopolamine patch for drooling. Pediatrics 1996;97(1):126-127. View abstract.

Gordon C, Ben Aryeh H, Attias J, and et al. Effect of transdermal scopolamine on salivation. J.Clin.Pharmacol. 1985;25(6):407-412. View abstract.

Gordon C, Binah O, Attias J, and et al. Transdermal scopolamine: human performance and side effects. Aviat.Space Environ.Med. 1986;57(3):236-240. View abstract.

Gordon C, Shupak A, Doweck I, and et al. Allergic contact dermatitis caused by transdermal hyoscine. BMJ 5-6-1989;298(6682):1220-1221. View abstract.

Goulston K. Diagnosis and treatment of the irritable bowel syndrome. Drugs 1973;6(3):237-243. View abstract.

Gowans, J., Matheson, A., Darlington, C. L., and Smith, P. F. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans. J Vestib.Res 2000;10(2):87-92. View abstract.

Grainger, S. L. and Smith, S. E. Dose-response relationships of intravenous hyoscine butylbromide and atropine sulphate on heart rate in healthy volunteers. Br J Clin Pharmacol 1983;16(6):623-626. View abstract.

Grasby P, Frith C, Paulesu E, and et al. The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. Exp Brain Res 1995;104(2):337-348. View abstract.

Gravenstein, J. S. and Thornby, J. I. Scopolamine on heart rates in man. Clin Pharmacol Ther 1969;10(3):395-400. View abstract.

Gravenstein, J. S., ANDERSEN, T. W., and DEPADUA, C. B. EFFECTS OF ATROPINE AND SCOPOLAMINE ON THE CARDIOVASCULAR SYSTEM IN MAN. Anesthesiology 1964;25:123-130. View abstract.

Graybiel A, Cramer D, and Wood C. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat.Space Environ.Med. 1982;53(8):770-772. View abstract.

Graybiel, A., Cramer, D. B., and Wood, C. D. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Aviat.Space Environ.Med 1981;52(6):337-339. View abstract.

Graybiel, A., Knepton, J., and Shaw, J. Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat.Space Environ Med 1976;47(10):1096-1100. View abstract.

Greenblatt D and Shader R. Drug therapy. Anticholinergics. N.Engl.J Med 6-7-1973;288(23):1215-1219. View abstract.

Greenstein A, Chen J, and Matzkin H. Transdermal scopolamine in prevention of post open prostatectomy bladder contractions. Urology 1992;39(3):215-218. View abstract.

Grynkiewicz, G. and Gadzikowska, M. Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs. Pharmacol.Rep. 2008;60(4):439-463. View abstract.

Guldbrand P and Mellstrom A. Rectal versus intramuscular morphine-scopolamine as premedication in children. Acta Anaesthesiol.Scand 1995;39(2):224-227. View abstract.

Habib, A., Sharpe, P., Anderson, S., Francis, S., Davidson, A. C., and Smith, G. Buscopan for the treatment of pain after laparoscopic sterilisation. Anaesthesia 2001;56(2):174-176. View abstract.

Hamill, M. B., Suelflow, J. A., and Smith, J. A. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle- closure glaucoma. Ann Ophthalmol 1983;15(11):1011-1012. View abstract.

Hamilton R, Perrone J, Meggs WJ, and et al. Epidemic anticholinergic poisoning from scopolamine tainted heroin [abstract]. NACCT Abstracts 1995;no volume listed:502.

Hamilton, R. J., Perrone, J., Hoffman, R., Henretig, F. M., Karkevandian, E. H., Marcus, S., Shih, R. D., Blok, B., and Nordenholz, K. A descriptive study of an epidemic of poisoning caused by heroin adulterated with scopolamine. J Toxicol Clin Toxicol 2000;38(6):597-608. View abstract.

Harnett, M. J., O'Rourke, N., Walsh, M., Carabuena, J. M., and Segal, S. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. Anesth.Analg. 2007;105(3):764-769. View abstract.

Harris, S. N., Sevarino, F. B., Sinatra, R. S., Preble, L., O'Connor, T. Z., and Silverman, D. G. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia. Obstet Gynecol 1991;78(4):673-677. View abstract.

Homick, J. L., Kohl, R. L., Reschke, M. F., Degioanni, J., and Cintron-Trevino, N. M. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat.Space Environ Med 1983;54(11):994-1000. View abstract.

Honer W, Prohovnik I, Smith G, and et al. Scopolamine reduces frontal cortex perfusion. J.Cereb.Blood Flow Metab 1988;8(5):635-641. View abstract.

Honkavaara P and Pyykko I. Effects of atropine and scopolamine on bradycardia and emetic symptoms in otoplasty. Laryngoscope 1999;109(1):108-112. View abstract.

Honkavaara P, Saarnivaara L, and Klemola U. Effect of transdermal hyoscine on nausea and vomiting after surgical correction of prominent ears under general anaesthesia. Br.J Anaesth. 1995;74(6):647-650. View abstract.

Honkavaara P, Saarnivaara L, and Klemola U. Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia. Br.J Anaesth. 1994;73(6):763-766. View abstract.

Honkavaara P. Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia. Br J Anaesth. 1996;76(1):49-53. View abstract.

Horimoto Y, Tomie H, Hanzawa K, and et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can.J Anaesth. 1991;38(4 Pt 1):441-444. View abstract.

Howland, J., Rohsenow, D. J., Minsky, S., Snoberg, J., Tagerud, S., Hunt, S. K., Almeida, A., Greece, J., and Allensworth-Davies, D. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup.Environ.Health 2008;14(4):250-256. View abstract.

Huff FJ, Mickel SF, Corkin S, and et al. Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Development Research 1988;12:271-278.

Hughes, S. S. and Zaloga, G. P. Scopolamine anisocaria. Ann Emerg.Med 1989;18(4):423-424. View abstract.

Hull S Jr., Vanoli E., Adamson P, and et.al. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation 5-15-1995;91(10):2516-2519. View abstract.

Ingles J, Beninger R, Jhamandas K, and et al. Scopolamine injected into the rat amygdala impairs working memory in the double Y-maze. Brain Res.Bull. 1993;32(4):339-344. View abstract.

Ison J and Bowen G. Scopolamine reduces sensitivity to auditory gaps in the rat, suggesting a cholinergic contribution to temporal acuity. Hear.Res 2000;145(1-2):169-176. View abstract.

Izquierdo, I. Mechanism of action of scopolamine as an amnestic. Trends Pharmacol Sci 1989;10(5):175-177. View abstract.

Jaaskelainen I, Hirvonen J, Huttunen J, and et al. Scopolamine enhances middle-latency auditory evoked magnetic fields. Neurosci.Lett. 1-4-1999;259(1):41-44. View abstract.

Jackson SH, Schmitt L, McGuire J, and et al. Transdermal scopolamine as a preanesthetic drug and postoperative antinauseant and antimetic [abstract]. Anesthesiology 1982;57(3):A330.

Jacobs, K. W. Asthmador: a legal hallucinogen. Int J Addict 1974;9(4):503-512. View abstract.

Jespersen, T. W., Koch, J., Anker-Moller, E., Spangsberg, N. L., Johansen, U. T., and Grydehoj, P. [Transdermal scopolamine to prevent postoperative nausea and vomiting after uterine curettage and termination of pregnancy. A double-blind clinically controlled study with placebo]. Ugeskr Laeger 5-15-1989;151(20):1246-1248. View abstract.

Jogani, V. V., Shah, P. J., Mishra, P., Mishra, A. K., and Misra, A. R. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis.Assoc.Disord. 2008;22(2):116-124. View abstract.

Johnson, P., Hansen, D., Matarazzo, D., Petterson, L., Swisher, C., and Trappolini, A. Transderm Scop for prevention of motion sickness. N.Engl.J Med 8-16-1984;311(7):468-469. View abstract.

Jones, D. M., Jones, M. E., Lewis, M. J., and Spriggs, T. L. Drugs and human memory: effects of low doses of nitrazepam and hyoscine on retention. Br J Clin Pharmacol 1979;7(5):479-483. View abstract.

Jones, S., Strobl, R., Crosby, D., Burkard, J. F., Maye, J., and Pellegrini, J. E. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron. AANA.J 2006;74(2):127-132. View abstract.

Kamboj, S. K. and Curran, H. V. Scopolamine induces impairments in the recognition of human facial expressions of anger and disgust. Psychopharmacology (Berl) 2006;185(4):529-535. View abstract.

Kanto J, Kentala E, and Kaila T. Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. Acta Anaesthesiol.Scand. 1989;33(6):482-486. View abstract.

Kashtan, H. I., Heyneker, T. J., and Morell, R. C. Atypical response to scopolamine in a patient with type IV hereditary sensory and autonomic neuropathy. Anesthesiology 1992;76(1):140-142. View abstract.

Kaye M, Rhodes J, and Sweetnam P. Clinical evaluation of three long-acting anticholinergic compounds. Gut 1968;9(5):590-596. View abstract.

Kentala E, Scheinin H, Kaila T, and et al. Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. Acta Anaesthesiol.Scand 1998;42(3):323-328. View abstract.

Kentala, E., Kaila, T., Arola, M., Mattila, M., and Kanto, J. Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. Eur J Anaesthesiol. 1991;8(2):135-140. View abstract.

Khadra I, Scott GC, and Braun SR. Transdermal scopolamine attenuates airways reactivity in asymptomatic asthmatics [abstract]. Am Rev Resp Dis 1988;137:329.

Kikuchi M, Wada Y, Nanbu Y, and et al. EEG changes following scopolamine administration in healthy subjects. Quantitative analysis during rest and photic stimulation. Neuropsychobiology 1999;39(4):219-226. View abstract.

Kim E and Jeong D. Transdermal scopolamine alters phasic REM activity in normal young adults. Sleep 6-15-1999;22(4):515-520. View abstract.

Kiyama S. A simple test for scopolamine mydriasis. Anesth.Analg. 1991;73(6):824. View abstract.

Klein, B. L., Ashenburg, C. A., and Reed, M. D. Transdermal scopolamine intoxication in a child. Pediatr Emerg.Care 1985;1(4):208-209. View abstract.

Klocker, N., Hanschke, W., Toussaint, S., and Verse, T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur.J Pharm Sci 2001;13(2):227-232. View abstract.

Knott VJ, Harr A, and Ilivitsky V. EEG correlates of acute nicotinic and muscarinic cholinergic blockade: separate and combined administration of mecamylamine and scopolamine in normal human subjects. Hum Psychopharmacol 1997;12:573-582.

Knott VJ, Harr A, and Ilivitsky V. Separate and combined effects of scopolamine and mecamylamine on human event-related brain potentials. Hum Psychopharmacol 1999;14:307-317.

Kohl R, Sandoz G, Reschke M, and et al. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J Clin Pharmacol 1993;33(11):1092-1103. View abstract.

Kompanje, E. J. O. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive & Critical Care Nursing 2006;22(4):214-219.

Koski E, Mattila M, Knapik D, and et al. Double blind comparison of transdermal hyoscine and placebo for the prevention of postoperative nausea. Br.J.Anaesth. 1990;64(1):16-20. View abstract.

Kotelko D, Rottman R, Wright W, and et al. Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine. Anesthesiology 1989;71(5):675-678. View abstract.

Kramer U and Harel S. Transdermal scopolamine for refractory seizures. J Child Neurol. 1997;12(2):139-141. View abstract.

Kventsel, I., Berkovitch, M., Reiss, A., Bulkowstein, M., and Kozer, E. Scopolamine treatment for severe extra-pyramidal signs following organophosphate (chlorpyrifos) ingestion. Clin.Toxicol.(Phila) 2005;43(7):877-879. View abstract.

La Rovere M, Mortara A, Pantaleo P, and et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90(2):838-843. View abstract.

Lahdes, K., Huupponen, R., Kaila, T., Salminen, L., and Iisalo, E. Systemic absorption of ocular scopolamine in patients. J Ocul.Pharmacol 1990;6(1):61-66. View abstract.

Laitinen, L. A., Tokola, O., Gothoni, G., and Vapaatalo, H. Scopolamine alone or combined with ephedrine in seasickness: a double- blind, placebo-controlled study. Aviat Space Environ Med 1981;52(1):6-10. View abstract.

Lauwers L, Daelemans R, Baute L, and et al. Scopolamine intoxications. Intensive Care Med. 1983;9(5):283-285. View abstract.

Lee T, Su S, Chen M, and et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am.J Cardiol. 8-15-1996;78(4):480-482. View abstract.

Lepore F. More on cycloplegia from transdermal scopolamine. N.Engl.J.Med. 9-23-1982;307(13):824. View abstract.

Lewis D, Fontana C, Mehallick L, and et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev.Med Child Neurol. 1994;36(6):484-486. View abstract.

Liljequist, R. and Mattila, M. J. Effect of physostigmine and scopolamine on the memory functions of chess players. Med Biol 1979;57(6):402-405. View abstract.

Lin, Y. C. Anisocoria from transdermal scopolamine. Paediatr Anaesth. 2001;11(5):626-627. View abstract.

Lines CR, Ambrose JH, Heald A, and et al. A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. Hum Pyschopharmacol 1993;8(4):271-278.

List WF and Gravenstein JS. Effects of atropine and scopolamine on the cardiovascular system in man. 2. Secondary bradycardia after scopolamine. Anesthesiology 1965;26(3):299-304.

Lloret J, Muñoz J, Monmany J, and et al. Treatment of renal colic with dipyrone. A double-blind comparison trial with hyoscine alone or combined with dipyrone. Curr Ther Res 1987;42(6):1119-1128.

Longo D, Howser D, Wesley M, and et al. Randomized double-blind crossover trial of scopolamine vs. placebo administered by transcutaneous patch for the control of chemotherapy-induced emesis [abstract]. Proc Am Assoc Cancer Res 1981;22:161.

Longo, D. L., Wesley, M., Howser, D., Hubbard, S. M., Anderson, T., and Young, R. C. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat.Rep 1982;66(11):1975-1976. View abstract.

Loper, K. A., Ready, L. B., and Dorman, B. H. Prophylactic transdermal scopolamine patches reduce nausea in postoperative patients receiving epidural morphine. Anesth.Analg. 1989;68(2):144-146. View abstract.

Love DC. Anisocoria from scopolamine patches. JAMA 10-4-1985;254(13):1720-1721. View abstract.

MacEwan G, Remick R, and Noone J. Psychosis due to transdermally administered scopolamine. CMAJ. 9-1-1985;133(5):431-432. View abstract.

Magalini, M. and Monica, F. [Use of prifinium bromide in endoscopic premedication. A double-blind controlled study vs hyoscine N-butylbromide]. Minerva Gastroenterol Dietol. 1995;41(2):197-202. View abstract.

Maher, R., Phillips-Hughes, J., Banning, A., and Boardman, P. The frequency and significance of silent myocardial ischemia due to hyoscine butylbromide use in peripheral angiography. Cardiovasc.Intervent.Radiol. 1999;22(5):369-374. View abstract.

Markkanen, Y. J. and Pihlajamaki, K. Oral scopolamine hydrobromide solution as an antisialagogic agent in dentistry. Oral Surg Oral Med Oral Pathol 1987;63(4):417-420. View abstract.

Marneros, A., Gutmann, P., and Uhlmann, F. Self-amputation of penis and tongue after use of Angel's Trumpet. Eur.Arch.Psychiatry Clin.Neurosci. 2006;256(7):458-459. View abstract.

Massoud, T. F. and Nolan, D. J. Dose reduction of hyoscine-N-butylbromide for double-contrast barium meal examinations--a prospective randomized study. Clin Radiol. 1992;46(5):340-343. View abstract.

Maus TL, Larsson LI, and Brubaker RF. Ocular effects of scopolamine dermal patch in open-angle glaucoma. J Glaucoma 1994;3(3):190-194.

McCauley M, Royal J, Shaw J, and et al. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat.Space Environ.Med. 1979;50(11):1108-1111. View abstract.

McCracken J, Poland R, Lutchmansingh P, and et al. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. Biol.Psychiatry 10-1-1997;42(7):577-584. View abstract.

McCracken J, Poland R, Rubin R, and et al. Dose-dependent effects of scopolamine on nocturnal growth hormone secretion in normal adult men: relation to delta-sleep changes. J Clin Endocrinol.Metab 1991;72(1):90-95. View abstract.

McCrary, J. A., III and Webb, N. R. Anisocoria from scopolamine patches. JAMA 7-16-1982;248(3):353-354. View abstract.

Mego, D. M., Omori, J. M., and Hanley, J. F. Transdermal scopolamine as a cause of transient psychosis in two elderly patients. South.Med J 1988;81(3):394-395. View abstract.

Meijer, J. W., van Kuijk, A. A., Geurts, A. C., Schelhaas, H. J., and Zwarts, M. J. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am.J Phys.Med Rehabil. 2008;87(4):321-324. View abstract.

Mercadante, S., Ripamonti, C., Casuccio, A., Zecca, E., and Groff, L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support.Care Cancer 2000;8(3):188-191. View abstract.

Messer SN. Homeopathic treatment of pediatric otitis media. J Am-Inst Homepathy 1987;80:15-21.

Meyer BR, Lewin M, Pasmantier M, and et al. Clinical trial of diazepam or scopolamine with metoclopramide to ameliorate cis-platinum induced emesis [abstract]. Clin Pharmacol Ther 1983;33 :222.

Meyer, B. R., O'Mara, V., and Reidenberg, M. M. A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol 1987;5(12):1994-1997. View abstract.

Millan, M. J., Di Cara, B., Dekeyne, A., Panayi, F., De Groote, L., Sicard, D., Cistarelli, L., Billiras, R., and Gobert, A. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem. 2007;100(4):1047-1061. View abstract.

Miller, E. K. and Desimone, R. Scopolamine affects short-term memory but not inferior temporal neurons. Neuroreport 1993;4(1):81-84. View abstract.

Mintzer, M. Z. and Griffiths, R. R. Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. Cogn Affect.Behav.Neurosci. 2007;7(2):120-129. View abstract.

Mirakhur, R. K. Comparative study of the effects of oral and i.m. atropine and hyoscine in volunteers. Br J Anaesth. 1978;50(6):591-598. View abstract.

Miyoshi A. A multi-centre, double-blind evaluation against placebo of the therapeutic effect of hyosine-N-butylbromide in patients with abdominal pain. Pharmatherapeutica 1976;1(1):46-51.

Molchan S, Martinez R, Hill J, and et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res.Brain Res.Rev. 1992;17(3):215-226. View abstract.

Molchan S, Matochik J, Zametkin A, and et al. A double FDG/PET study of the effects of scopolamine in older adults. Neuropsychopharmacology 1994;10(3):191-198. View abstract.

Molchan, S. E., Hill, J. L., Minichiello, M., Vitiello, B., and Sunderland, T. Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans. Life Sci 1994;54(13):933-938. View abstract.

Mora Durban MJ, Extramiana Cameno J, Arrizabalaga Moreno M, and et al. [Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic] (spanish). Arch Esp Urol 1995;48(9):867-873.

Morrison, J. D. and Reilly, J. The effects of 0.025% hyoscine hydrobromide eyedrops on visual function in man. Ophthalmic Physiol Opt. 1989;9(1):41-45. View abstract.

Moscovici R, Prego G, Schwartz M, and et al. Epidural scopolamine administration in preventing nausea after epidural morphine. J Clin Anesth. 1995;7(6):474-476. View abstract.

Mukerji V, Alpert M, Sanfelippo J, and et al. Treatment of chronic symptomatic supraventricular bradyarrhythmias with transdermal scopolamine. Chest 1988;94(1):204-205. View abstract.

Mundy LR and Zeller WW. Acute toxic psychosis due to scopolamine (a case report). Dis Nerv Sys 1958;19:423-424.

Muskat Y, Bukovsky I, Schneider D, and et al. The use of scopolamine in the treatment of detrusor instability. J Urol. 1996;156(6):1989-1990. View abstract.

Nachum, Z., Shahal, B., Shupak, A., Spitzer, O., Gonen, A., Beiran, I., Lavon, H., Eynan, M., Dachir, S., and Levy, A. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001;296(1):121-123. View abstract.

Nachum, Z., Shupak, A., and Gordon, C. R. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin.Pharmacokinet. 2006;45(6):543-566. View abstract.

Neufeld M, Rabey M, Parmet Y, and et al. Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. Electroencephalogr.Clin Neurophysiol. 1994;91(6):407-412. View abstract.

Newhouse, P. A., Sunderland, T., Tariot, P. N., Weingartner, H., Thompson, K., Mellow, A. M., Cohen, R. M., and Murphy, D. L. The effects of acute scopolamine in geriatric depression. Arch Gen.Psychiatry 1988;45(10):906-912. View abstract.

Nieto J, Abizanda J, Pico F, Valenzuela G, and et al. Transdermal scopolamine as treatment of bradyarrhythmias. Chest 1992;101(6):1588-1590. View abstract.

No authors. Putting a patch on postop nausea. Nursing 2007;37(1):0.

Nogue S, Sanz P, Munne P, and et al. Acute scopolamine poisoning after sniffing adulterated cocaine. Drug Alcohol Depend. 1991;27(2):115-116. View abstract.

Noy S, Shapira S, Zilbiger A, and et al. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea. Aviat.Space Environ.Med 1984;55(11):1051-1054. View abstract.

Nuotto, E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. Eur J Clin Pharmacol 1983;24(5):603-609. View abstract.

Nussdorf, J. D. and Berman, E. L. Anisocoria associated with the medical treatment of irritable bowel syndrome. J Neuroophthalmol. 2000;20(2):100-101. View abstract.

Obonsawin MC, Goddard C, Crawford JR, and et al. The effects of scopolamine on the recall of repeated words: a preliminary investigation. Hum Psychopharmacol 1996;11:25-31.

Offenloch, K., Zahner, G., Dietlein, G., and Franz, I. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions]. Arzneimittelforschung. 1986;36(9):1401-1406. View abstract.

Ohkawa, T., Morimoto, S., Okuyama, A., Yoshioka, T., Kishimoto, T., Kurita, T., Ikoma, F., Itatani, H., Koide, T., and Ogawa, N. [Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group]. Hinyokika Kiyo 1997;43(7):525-538. View abstract.

Osterholm R and Camoriano J. Transdermal scopolamine psychosis. JAMA 6-11-1982;247(22):3081. View abstract.

Ostfeld AM and Aruguete A. Central nervous system effects of hyoscine in man. J Pharmacol Exp Ther 1962;137:133-139.

Paasuke, R. T. Transdermally administered scopolamine. Canadian Medical Association Journal 11-15-1985;133(10):956. View abstract.

Palm L and Blennow G. Transdermal anticholinergic treatment of reflex anoxic seizures. Acta Paediatr.Scand. 1985;74(5):803-804. View abstract.

Pan, S. Y. and Han, Y. F. Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice. Pharmacology 2004;72(3):177-183. View abstract.

Paphassarang S, Raynaud J, Godeau RP, and et al. Analyses qualitatives et quantitatives de la hyoscyamine-atropine et de la scopolamine dans les teintures meres de Solanacees par chromatographie liquide haute performance [Qualitative and quantitative analyses of hyoscyamine-atropine and scopolamine in the dyeings mothers of Solanacees by liquid chromatography]. J Chromatogr 1985;319:412-418.

Park, K. W. and Lowenstein, E. Acute complete heart block during anesthesia in a patient with severe coronary artery disease: effect of scopolamine versus ischemia of the AV node. Anesthesiology 1991;75(2):367-370. View abstract.

Parrott A and Jones R. Effects of transdermal scopolamine upon psychological test performance at sea. Eur.J.Clin.Pharmacol. 1985;28(4):419-423. View abstract.

Parrott A and Wesnes K. Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects. Psychopharmacology (Berl) 1987;92(4):513-519. View abstract.

Parrott A. The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance. Psychopharmacology (Berl) 1986;89(3):347-354. View abstract.

Parrott AC, Golding JF, and Pethybridge RJ. The effects of single and repeated doses of oral scopolamine, cinnarizine, and placebo upon psychological performance and physiological functioning. Hum Psychopharmacol 1990;5(3):207-216.

Parrott AC. Transdermal scopolamine: effects of single and repeated patches upon aspects of vision. Hum Psychopharmacol 1986;1:109-115.

PASSMORE, G. G. and SANTA CRUZ, E. W. The use of intravenous and intramuscular injections of demerol and scopolamine in labor and delivery. Am.J Obstet.Gynecol 1954;68(4):998-1008. View abstract.

Pearn J. Corked up: clinical hyoscine poisoning with alkaloids of the native corkwood, Duboisia. Med.J.Aust. 10-17-1981;2(8):422-423. View abstract.

Pedersen JE. Scopolamine as sole pre-anaesthetic medication. Acta Anaesth Scandinav 1963;7:121-129.

Pedretti R, Colombo E, and Braga S. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction. Am.J Cardiol. 8-15-1993;72(5):384-392. View abstract.

Perrone J, Hamilton R, Nelson L, and et al. From the Centers for Disease Control and Prevention. Scopolamine poisoning among heroin users--New York City, Newark, Philadelphia, and Baltimore, 1995 and 1996. JAMA 7-10-1996;276(2):92-93. View abstract.

Petersen, R. C. Scopolamine induced learning failures in man. Psychopharmacology (Berl) 5-9-1977;52(3):283-289. View abstract.

Pfeiffer, A., Kaess, H., Bodeker, R. H., and Schwantes, U. Heart rate increase after intravenous administration of trospium chloride and scopolamine during endoscopic retrograde cholangiopancreatography. Endoscopy 1999;31(6):507. View abstract.

Pihlajamaki K, Kanto J, and Oksman-Caldentey K. Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. Acta Pharmacol Toxicol.(Copenh) 1986;59(4):259-262. View abstract.

Pihlajamaki, K., Hovi-Viander, M., and Kanto, J. Effect of induced hypotension on serum concentrations of atropine after intramuscular administration. Acta Anaesthesiol Scand 1986;30(1):64-65. View abstract.

Pingree, B. J. and Pethybridge, R. J. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness. Aviat.Space Environ Med 1994;65(7):597-605. View abstract.

Poland R, McCracken J, Lutchmansingh P, and et al. Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects. Biol.Psychiatry 5-1-1997;41(9):929-938. View abstract.

Poland R, Tondo L, and Rubin R. Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol abnormalities in depression. Biol.Psychiatry 2-15-1989;25(4):403-412. View abstract.

Pontecorvo M, Clissold D, White M, and et al. N-methyl-D-aspartate antagonists and working memory performance: comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine. Behav.Neurosci. 1991;105(4):521-535. View abstract.

Potter D, Pickles C, Roberts R, and et al. The effects of scopolamine on event-related potentials in a continuous recognition memory task. Psychophysiology 1992;29(1):29-37. View abstract.

Poynard, T., Regimbeau, C., and Benhamou, Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment.Pharmacol Ther 2001;15(3):355-361. View abstract.

Price B. Anisocoria from scopolamine patches. JAMA 3-15-1985;253(11):1561. View abstract.

Price N, Schmitt L, McGuire J, and et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin.Pharmacol.Ther. 1981;29(3):414-419. View abstract.

Price N, Schmitt LG, and Shaw JE. Transdermal delivery of scopolamine for prevention of motion-induced nausea in rough seas. Clin Ther 1979;2:258-262.

Putcha L, Tietze K, Bourne D, and et al. Bioavailability of intranasal scopolamine in normal subjects. J Pharm.Sci. 1996;85(8):899-902. View abstract.

Putcha, L., Cintron, N. M., Tsui, J., Vanderploeg, J. M., and Kramer, W. G. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharmaceutical Research 1989;6(6):481-485. View abstract.

Pyykko I, Schalen L, and Jantti V. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol. 1985;99(5-6):588-596. View abstract.

Pyykko I, Schalen L, Jantti V, and et al. A reduction of vestibulo-visual integration during transdermally administered scopolamine and dimenhydrinate. A presentation of gain control theory in motion sickness. Acta Otolaryngol.Suppl 1984;406:167-173. View abstract.

Pyykko, I., Padoan, S., Schalen, L., Lyttkens, L., Magnusson, M., and Henriksson, N. G. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat.Space Environ Med 1985;56(8):777-782. View abstract.

Pyykko, I., Schalen, L., and Matsuoka, I. Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on different types of nystagmus. Acta Otolaryngol. 1985;99(5-6):597-604. View abstract.

Rabey, J. M., Neufeld, M. Y., Treves, T. A., Sifris, P., and Korczyn, A. D. Cognitive effects of scopolamine in dementia. J Neural Transm.Gen Sect. 1996;103(7):873-881. View abstract.

Raeder, E. A., Stys, A., and Cohen, R. J. Effect of low-dose scopolamine on autonomic control of the heart. Ann Noninvasive.Electrocardiol. 1997;2(3):236-241. View abstract.

Raeder, J. C., van der, Linden J., and Breivik, H. Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine. Acta Anaesthesiol.Scand 1986;30(7):502-506. View abstract.

Rahko, T. and Karma, P. Transdermal scopolamine for peripheral vertigo (a double-blind study). J Laryngol Otol 1985;99(7):653-656. View abstract.

Ramadan, M. Moonflower intoxication in Kansas. Am.J Addict. 2005;14(4):399-400. View abstract.

Rao U, Lutchmansingh P, and Poland R. Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression. Neuropsychopharmacology 1999;21(6):723-730. View abstract.

Rasmusson, D. D. and Dudar, J. D. Effect of scopolamine on maze learning performance in humans. Experientia 8-15-1979;35(8):1069-1070. View abstract.

Recto CP, Co TV, and Clemente V. The effect of hyoscine-n-butylbromide on the first stage of labor: a clinical trial [abstract]. Acta Obstetricia et Gynecologica Scandinavica Supplement 1997;76(167):45.

Reinhart D, Klein K, and Schroff E. Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study. Anesth.Analg. 1994;79(2):281-284. View abstract.

Richardson J, Frith C, Scott E, and et al. The effects of intravenous diazepam and hyoscine upon recognition memory. Behav.Brain Res. 1984;14(3):193-199. View abstract.

Richardson, C. T. and Feldman, M. Effects of transdermal scopolamine, alone or in combination with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer. Gut 1986;27(12):1493-1497. View abstract.

Riemann D, Hohagen F, Fleckenstein P, and et al. The cholinergic REM induction test with RS 86 after scopolamine pretreatment in healthy subjects. Psychiatry Res 1991;38(3):247-260. View abstract.

Ripamonti, C., Mercadante, S., Groff, L., Zecca, E., De Conno, F., and Casuccio, A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom.Manage 2000;19(1):23-34. View abstract.

Ritchie, J. A. and Truelove, S. C. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 2-10-1979;1(6160):376-378. View abstract.

Robbins T, Semple J, umar R, and t al. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. Psychopharmacology (Berl) 1997;134(1):95-106. View abstract.

Rodysill, K. J. and Warren, J. B. Transdermal scopolamine and toxic psychosis. Ann Intern Med 1983;98(4):561. View abstract.

Rogawski M. Transdermal scopolamine and sialorrhea. Arch.Neurol. 1984;41(1):15. View abstract.

Rosen N. Accidental mydriasis from scopolamine patches. J Am.Optom.Assoc. 1986;57(7):541-542. View abstract.

Rosenberg M. Preoperative anisocoria from a scopolamine patch. Anesth.Analg. 1987;66(7):693. View abstract.

Rosier A, Cornette L, and Orban G. Scopolamine-induced impairment of delayed recognition of abstract visual shapes. Neuropsychobiology 1998;37(2):98-103. View abstract.

Rosier, A. M., Cornette, L., Dupont, P., Bormans, G., Mortelmans, L., and Orban, G. A. Regional brain activity during shape recognition impaired by a scopolamine challenge to encoding. Eur J Neurosci. 1999;11(10):3701-3714. View abstract.

Rubin M, Sadoff R, and Cozzi G. Unilateral mydriasis caused by transdermal scopolamine. Oral Surg.Oral Med Oral Pathol. 1990;70(5):569-570. View abstract.

Rusted J and Eaton-Williams P. Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall. Psychopharmacology (Berl) 1991;104(3):363-366. View abstract.

Rusted J and Warburton D. The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology (Berl) 1988;96(2):145-152. View abstract.

Rusted J, Eaton-Williams P, and Warburton D. A comparison of the effects of scopolamine and diazepam on working memory. Psychopharmacology (Berl) 1991;105(3):442-445. View abstract.

Rusted J. Dissociative effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology (Berl) 1988;96(4):487-492. View abstract.

Rusted, J. M. and Warburton, D. M. Effects of scopolamine on verbal memory; a retrieval or acquisition deficit? Neuropsychobiology 1989;21(2):76-83. View abstract.

Safer, D. J. and Allen, R. P. The central effects of scopolamine in man. Biol Psychiatry 1971;3(4):347-355. View abstract.

Sagales, T., Erill, S., and Domino, E. F. Differential effects of scopolamine and chlorpromazine on REM and NREM sleep in normal male subjects. Clin Pharmacol Ther 1969;10(4):522-529. View abstract.

Samuels, L. A., Christie, L., Roberts-Gittens, B., Fletcher, H., and Frederick, J. The effect of hyoscine butylbromide on the first stage of labour in term pregnancies. BJOG. 2007;114(12):1542-1546. View abstract.

Sannita W, Maggi L, and Rosadini G. Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers. Neuropsychobiology 1987;17(4):199-205. View abstract.

Sannita WG, Fioretto M, Maggi L, and et al. Effects of scopolamine parenteral administration on the electroretinogram, visual evoked potentials, and quantitive electroencephalogram of healthy volunteers. Documenta Ophthamologica 1988;67:379-390.

Sannita, W. G., Balestra, V., DiBon, G., Marotta, V., and Rosadini, G. Human flash-VEP and quantitative EEG are independently affected by acute scopolamine. Electroencephalogr.Clin Neurophysiol. 1993;86(4):275-282. View abstract.

Sauder CL, Shalansky KF, and Hewko RA. Transdermal scopolamine and transient psychosis. Can J Hosp Pharm 1994;47(2):67-69.

Scheurlen M, Antonin K, and Bieck P. Effect of low-dose anticholinergic treatment with transdermal scopolamine (Transderm

Schifano F and Curran H. Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall. Psychopharmacology (Berl) 1994;115(3):430-434. View abstract.

Schmitt, L. G. and Shaw, J. E. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine. Arch Otolaryngol.Head Neck Surg 1986;112(1):88-91. View abstract.

Schneider, M. and Palas, T. A. [Morphine and scopolamine in premedication. A comparison of peroral and transdermal administration with intramuscular injections]. Anaesthesist 1986;35(3):193-196. View abstract.

Semple P, Madej T, Wheatley R, and et al. Transdermal hyoscine with patient-controlled analgesia. Anaesthesia 1992;47(5):399-401. View abstract.

Sennhauser F and Schwarz H. Toxic psychosis from transdermal scopolamine in a child. Lancet 11-1-1986;2(8514):1033. View abstract.

Shojaku H, Watanabe Y, Ito M, and et al. Effect of transdermally administered scopolamine on the vestibular system in humans. Acta Otolaryngol.Suppl 1993;504:41-45. View abstract.

Shupak A, Gordon C, Spitzer O, and et al. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Pharmatherapeutica 1989;5(6):365-370. View abstract.

Sieg, H. [Double blind test using hyoscine-N-butyl bromide (Buscopan) to reduce pain in ulcus ventriculi]. Z Gastroenterol 1974;12(4):235-238. View abstract.

Siegel L and Klingbeil M. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev.Med Child Neurol. 1991;33(11):1013-1014. View abstract.

Sitaram, N., Moore, A. M., and Gillin, J. C. Induction and resetting of REM sleep rhythm in normal man by arecholine: blockade by scopolamine. Sleep 1978;1(1):83-90. View abstract.

Sitaram, N., Moore, A. M., and Gillin, J. C. Scopolamine-induced muscarinic supersensitivity in normal man: changes in sleep. Psychiatry Res 1979;1(1):9-16. View abstract.

Soares, P. P., Porto, C. S., Abdalla, F. M., De La Fuente, R. N., Moreira, E. D., Krieger, E. M., and Irigoyen, M. C. Effects of rat sinoaortic denervation on the vagal responsiveness and expression of muscarinic acetylcholine receptors. J Cardiovasc.Pharmacol. 2006;47(3):331-336. View abstract.

Solomon P, Groccia-Ellison M, Flynn D, and et al. Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine. Behav.Neurosci. 1993;107(2):271-279. View abstract.

Spinks, A. B., Wasiak, J., Villanueva, E. V., and Bernath, V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane.Database.Syst.Rev. 2007;(3):CD002851. View abstract.

Spinks, A. B., Wasiak, J., Villanueva, E. V., and Bernath, V. Scopolamine for preventing and treating motion sickness. Cochrane.Database.Syst.Rev 2004;(3):CD002851. View abstract.

Stetina, P. M., Madai, B., Kulemann, V., Kirch, W., and Joukhadar, C. Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. Int J Clin.Pharmacol.Ther. 2005;43(3):134-139. View abstract.

Stieg, R. L. Double-blind study of belladonna-ergotamine-phenobarbital for interval treatment of recurrent throbbing headache. Headache 1977;17(3):120-124. View abstract.

Strom B, CarsonJ, Schinnar R, and et al. No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology. Clin Pharmacol Ther 1991;50(1):107-113. View abstract.

Stromberg B, Reines D, and Ackerly J. Transderm scopolamine for the control of perioperative nausea. Am.Surg. 1991;57(11):712-715. View abstract.

Sunderland T, Esposito G, Molchan S, and et al. Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology (Berl) 1995;121(2):231-241. View abstract.

Sunderland T, Tariot P, Cohen R, and et.al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch.Gen.Psychiatry 1987;44(5):418-426. View abstract.

Sunderland, T., Tariot, P., Murphy, D. L., Weingartner, H., Mueller, E. A., and Cohen, R. M. Scopolamine challenges in Alzheimer's disease. Psychopharmacology (Berl) 1985;87(2):247-249. View abstract.

Talmi Y, Finkelstein Y, and Zohar Y. Reduction of salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS. Head Neck 1989;11(6):565. View abstract.

Talmi Y, Finkelstein Y, and Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four-year experience. Otolaryngol.Head Neck Surg. 1990;103(4):615-618. View abstract.

Talmi Y, Finkelstein Y, Zohar Y, and et al. Reduction of salivary flow with Scopoderm TTS. Ann.Otol.Rhinol.Laryngol. 1988;97(2 Pt 1):128-130. View abstract.

Tariot P, Patel S, Cox C, and et al. Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology (Berl) 1996;125(1):50-56. View abstract.

Tarkkila P, Torn K, Tuominen M, and et al. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol.Scand 1995;39(7):983-986. View abstract.

Thiele, E. A. and Riviello, J. J. Scopolamine patch-induced unilateral mydriasis. Pediatrics 1995;96(3 Pt 1):525. View abstract.

Thomas, E., Snyder, P. J., Pietrzak, R. H., Jackson, C. E., Bednar, M., and Maruff, P. Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia 2008;46(10):2476-2484. View abstract.

Thune, A., Appelgren, L., and Haglind, E. Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. Eur J Surg 1995;161(4):265-268. View abstract.

Tigerstedt I, Salmela L, and Aromaa U. Double-blind comparison of transdermal scopolamine, droperidol and placebo against postoperative nausea and vomiting. Acta Anaesthesiol.Scand. 1988;32(6):454-457. View abstract.

Tokola, O., Laitinen, L. A., Aho, J., Gothoni, G., and Vapaatalo, H. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations. Aviat.Space Environ Med 1984;55(7):636-641. View abstract.

Tolksdorf, W., Baumann, S., Heine, C., and Hettenbach, A. [Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients]. Anasth.Intensivther.Notfallmed. 1986;21(6):301-306. View abstract.

Tolksdorf, W., Meisel, R., Muller, P., and Bender, H. J. [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting]. Anaesthesist 1985;34(12):656-662. View abstract.

Tonndorf J, Hyde RW, Chinn HI, and et al. Absorption from nasal mucous membrane: systemic effect of hyoscine following intranasal administration. Ann Otol Rhinol Laryngol 1953;62:630-641.

Toscano, A., Pancaro, C., and Peduto, V. A. Scopolamine prevents dreams during general anesthesia. Anesthesiology 2007;106(5):952-955. View abstract.

Trõster AI, Beatty WW, Staton RD, and et al. Effects of scopolamine on anterograde and remote memory in humans. Psychobiology 1989;17(1):12-18.

Trozak, D. J. Delayed hypersensitivity to scopolamine delivered by a transdermal device. J.Am.Acad.Dermatol. 1985;13(2 Pt 1):247-251. View abstract.

Tsuji, M. H. and Yamashita, M. [Scopolamine butylbromide (0.2 mg.kg-1) prevents succinylcholine- induced bradycardia in infants and children]. Masui 1992;41(4):670-672. View abstract.

Tytgat, G. N. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007;67(9):1343-1357. View abstract.

Uppington J, Dunnet J, and Blogg C. Transdermal hyoscine and postoperative nausea and vomiting. Anaesthesia 1986;41(1):16-20. View abstract.

Valentine, S., McVey, F. K., and Coe, A. Postoperative sore throat. A comparison after premedication with papaveretum/hyoscine or temazepam. Anaesthesia 1990;45(4):306-308. View abstract.

Van der Burg, J. J., Jongerius, P. H., Van, Hulst K., Van, Limbeek J., and Rotteveel, J. J. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev.Med Child Neurol. 2006;48(2):103-107. View abstract.

van der Willigen A, Oranje A, Stoltz E, and et al. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems. J Am.Acad.Dermatol. 1988;18(1 Pt 1):146-147. View abstract.

van Marion, W. F., Bongaerts, M. C., Christiaanse, J. C., Hofkamp, H. G., and van Ouwerkerk, W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin Pharmacol Ther 1985;38(3):301-305. View abstract.

Venkatesh G, Fallen E, Kamath M, and et al. Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure. Heart 1996;76(2):137-143. View abstract.

Verdier D and Kennerdell J. Fixed dilated pupil resulting from transdermal scopolamine. Am.J.Ophthalmol. 1982;93(6):803-804. View abstract.

Vesalainen R, Tahvanainen K, and Kaila T. Effects of low-dose transdermal scopolamine on autonomic cardiovascular control in healthy young subjects. Clin Physiol 1997;17(2):135-148. View abstract.

Vesalainen, R. K., Kaila, T. J., Kantola, I. M., Tahvanainen, K. U., Juhani Airaksinen, K. E., Kuusela, T. A., and Eckberg, D. L. Low-dose transdermal scopolamine decreases blood pressure in mild essential hypertension. J Hypertens. 1998;16(3):321-329. View abstract.

Villanueva E, Clar C, Wasiak J, and et al. Scopolamine for preventing and treating motion sickness [protocol]. Cochrane Database Systematic Reviews 2001;(4)

Vybiral T, Bryg R, Maddens M, and et al. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am.J Cardiol. 3-1-1990;65(9):604-608. View abstract.

Vybiral T, Bryg R, Maddens M, and et al. Parasympathetic stimulation with transdermal scopolamine increases heart rate variability in acute myocardial infarction - a preliminary report [abstract]. Clin Res 1990;38(2):337A.

Vybiral T, Glaeser D, Morris G, and et al. Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction. J Am.Coll.Cardiol. 11-1-1993;22(5):1320-1326. View abstract.

Walan, A. Studies on peptic ulcer disease with special reference to the effect of l-hyoscyamine. Acta Med Scand Suppl 1970;516:5-57. View abstract.

Walt R, Kalman C, Hunt R, and et al. Effect of transdermally administered hyoscine methobromide on nocturnal acid secretion in patients with duodenal ulcer. Br.Med.J.(Clin Res.Ed) 6-12-1982;284(6331):1736-1738. View abstract.

Wang, E. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action]. Zhonghua Er.Bi Yan.Hou Ke.Za Zhi 1990;25(5):299-302, 319. View abstract.

Wee, B. and Hillier, R. Interventions for noisy breathing in patients near to death. Cochrane.Database.Syst.Rev. 2008;(1):CD005177. View abstract.

Wesnes K and Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology (Berl) 1984;84(1):5-11. View abstract.

Wesnes K and Warburton D. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl) 1984;82(3):147-150. View abstract.

Wesnes K and Warburton D. Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 1983;9(2-3):154-157. View abstract.

Wesnes K, Simpson P, and Kidd A. An investigation of the range of cognitive impairments induced by scopolamine 0

White, P. F., Tang, J., Song, D., Coleman, J. E., Wender, R. H., Ogunnaike, B., Sloninsky, A., Kapu, R., Shah, M., and Webb, T. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth.Analg. 2007;104(1):92-96. View abstract.

Whitlock, F. A. and Fama, P. G. Hyoscine poisoning in psychiatric practice. Med J Aust 10-15-1966;2(16):763-764. View abstract.

Wiener L, Baum N, and Suarez G. New method for management of detrusor instability: transdermal scopolamine. Urology 1986;28(3):208-210. View abstract.

Wilkinson A, Frampton C, Glover P, and et al. Preoperative transdermal hyoscine for the prevention of postoperative nausea and vomiting. Anaesth.Intensive Care 1989;17(3):285-289. View abstract.

Wilkinson J. Side effects of transdermal scopolamine. J Emerg.Med 1987;5(5):389-392. View abstract.

Wirsching B, Beninger R, and Jhamandas K. Differential effects of scopolamine on working and reference memory of rats in the radial maze. Pharmacol Biochem.Behav. 1984;20(5):659-662. View abstract.

Wood C, Manno J, Wood M, and et al. Mechanisms of antimotion sickness drugs. Aviat.Space Environ.Med 1987;58(9 Pt 2):A262-A265. View abstract.

Wood C, Stewart J, Wood M, and et al. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness. Aviat.Space Environ.Med 1990;61(2):157-161. View abstract.

Wood C. Antimotion sickness and antiemetic drugs. Drugs 1979;17(6):471-479. View abstract.

Wyant GM and Dobkin AB. Antisialogogue drugs in man. Comparison of atropine, scopolamine (l-hyoscine) and l-hyoscyamine (bellafoline). Anaesthesia 1957;12(2):203-214.

Yang MJ and Chen CC. Herbally induced anticholinergic intoxication: a report of three cases. Kaohsiung J Med Sci 1987;3:133-136.

Yang, G., Xu, K., and Luo, Q. [Clinical study of scopolamine detoxification for the treatment of heroin addicts]. Zhonghua Yi Xue.Za Zhi 1996;76(2):141-144. View abstract.

Ziskind, A. A. Transdermal scopolamine-induced psychosis. Postgrad Med 9-1-1988;84(3):73-76. View abstract.

Ebert U, Oertel R, Kirch W. Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. Int J Clin Pharmacol Ther 2000;38:523-31. View abstract.

Freeland-Graves JH, Lin PH. Plasma uptake of manganese as affected by oral loads of manganese, calcium, milk, phosphorus, copper, and zinc. J Am Coll Nutr 1991;10:38-43. View abstract.

Friese KH, Kruse S, Ludtke R, and et al. The homoeopathic treatment of otitis media in children--comparisons with conventional therapy. Int J Clin Pharmacol Ther 1997;35(7):296-301. View abstract.

Hsu CK, Leo P, Shastry D, et al. Anticholinergic poisoning associated with herbal tea. Arch Intern Med 1995;155:2245-8. View abstract.

Jie KG, Bots ML, Vermeer C, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 1996;59:352-6. View abstract.

Larsen SB and Peitersen E. Scopoderm-TTS® (scopolamine) influence on caloric-induced nystagmus: an extract. Advances in Oto-Rhino-Laryngol 1983;30:365-369.

Lean ME, Noroozi M, Kelly I. Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Diabetes 1999;48:176-81. View abstract.

Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 1991;42:111-20. View abstract.

CONTINUE SCROLLING FOR RELATED SLIDESHOW

Health Solutions From Our Sponsors